An Indiana-based pharmaceutical giant recently announced that it’s working to align its U.S. drug prices with those paid by other [...] …
Blog Posts
Two major drugmakers recently filed lawsuits challenging Maine’s new 340B contract pharmacy access law, drawing sharp criticism from an influential [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Swiss pharmaceutical giant this week announced new 340B contract pharmacy restriction exemptions for two states that recently enacted contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The number of drugmakers that have placed 340B contract pharmacy restrictions on health centers has more than doubled since the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two large pharmaceutical companies this week filed the first federal lawsuits challenging Rhode Island’s recently enacted 340B contract pharmacy access [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The U.S. drug pricing infrastructure is entering a transformative era. On August 1, 2025, the Health Resources and Services Administration (HRSA) announced a voluntary 340B Rebate Model Pilot, aligned with the Inflation Reduction Act’s Maximum Fair Price (MFP) provisions
…
The dark money group behind a campaign targeting GOP-led states’ efforts to enact 340B contract pharmacy access laws recently released [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Trade groups representing 340B hospitals and hospital pharmacists recently urged the Health Resources and Services Administration (HRSA) to extend the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A prestigious health care think tank recently offered an overview of the 340B program—including criticisms surrounding its growth and drugmakers’ [...] …